Mind Medicine (MNMD 9.04%) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% as of 2 p.m. ET despite a 0.8% pullback for the S&P 500 index and a 1.5% decline for the Nasdaq Composite index.MindMed stock is surging today following a recent report from a Minnesota-based task force that urged the decriminalization of psychedelic mushrooms. The clinical-stage biotech specialist is focused on potential medical applications for psychedelics, and it stands to benefit if ...

Mind Medicine (MindMed) (MNMD) is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD).2024 Turns Out to Be a Transformational Year for MindMed2024 was a transformational year for the company when it executed many important milestones, one of which was initiating the 52-week Voyage phase III study on MM120 ODT in GAD ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This writing is for informational purposes only. All opinions expressed herein are not investment rec ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephanie Fagan – Chief Corporate Affairs Officer Rob Barrow – Chief Executive Officer Dan Karlin – Chief Medical Officer Conference Call Participants Madhu Yennawar – Leerink Partners James Nevin – RBC Capital Markets Charles Duncan – Cantor Francois Brisebois – Oppenheimer Patrick Trucchio – H.C. Wainwright Michael Okunewitch – Maxim Group Sumant Kulkarni – Canaccord Genuity Operato ...

Corporate Presentation November 2024 Disclaimer This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed) Inc. ("MindMed", the "Company", "we", "our" or "us) solely for informational purposes. This Presentation does not constitute an offering of, or a solicitation of an offer to purchase, securities of MindMed and under no circumstances is it to be construed as a prospectus or advertisement or public offering of securities. Any trademarks included herein are the property of the own ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

| --- | --- | --- | --- | --- | --- | |-------|-------|-----------------------|-----------------|-------|-------| | | | | | | | | | | | | | | | | | Second Quarter 2024 | | | | | | | | | | | | | | | | | | | | | Financial Results and | | | | | | | Business Updates | | | | | | | | August 13, 2024 | | | Disclaimer 2 This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed) Inc. ("MindMed", the "Company", "we", "our" or "us) solely for informational purposes. This Presentation does not ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET Company Participants Robert Barrow - CEO Daniel Karlin - CMO Reid Robison - Senior Principal Investigator, Cedar Clinical Research Conference Call Participants Elaine Kim - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Rudy Li - Leerink Partners LLC Daniel Hultberg - Oppenheimer Christopher Chen - Robert W. Baird Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to the Mind Me ...

Editor's note: Seeking Alpha is proud to welcome Jason Najum as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » Fokusiert The Food and Drug Administration (FDA) will soon announce a decision that could have serious repercussions for MindMed investors and the entire psychedelic medicine industry. For decades, an organization ...

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Mind Medicine (MindMed) Inc. is currently sporting a Zacks Rank of #2 (Buy). One other Medical stock that has outperformed the sector so far this year is ResMed (RMD) . The stock is up 23.5% year-to-date. Investors interested in the Medical sector may want to keep a close eye on Mind M ...